Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-1 Adjuvant Chemotherapy After Pancreatectomy
Loss of skeletal muscle mass during neoadjuvant chemotherapy for pancreatic cancer affected the continuation of S-1 adjuvant chemotherapy after pancreatic resection. Therefore, ameliorating loss of skeletal muscle mass during neoadjuvant chemotherapy should be carefully considered to improve the continuation rate of adjuvant chemotherapy and the survival of patients with pancreatic cancer.
Authors
- Satoshi Kobayashi (ORCID: https://orcid.org/0000-0002-7760-0771)
- Soichiro Morinaga
- Toru Aoyama
- Naoto Yamamoto (ORCID: https://orcid.org/0000-0003-0613-5451)
- Yosuke Atsumi (ORCID: https://orcid.org/0000-0002-1071-5486)
- Masaaki Murakawa (ORCID: https://orcid.org/0000-0001-6140-7953)
- ITARU HASHIMOTO (ORCID: https://orcid.org/0000-0002-8398-1494)
- Makoto Ueno (ORCID: https://orcid.org/0000-0003-4480-0029)
- Keisuke Kazama (ORCID: https://orcid.org/0000-0002-8155-8561)
- Norio Yukawa (ORCID: https://orcid.org/0000-0003-0411-6353)
- Aya Saito (ORCID: https://orcid.org/0000-0001-6731-2007)
- Rei Kanemoto
- Mariko Kamiya (ORCID: https://orcid.org/0000-0002-2867-423X)
- Takashi Oshima (ORCID: https://orcid.org/0000-0003-3349-2649)
- Yukio Maezawa
- SHINNOSUKE KAWAHARA
- Naohiko Matsushita
Institutions
- Kanagawa Prefectural Hospital Organization (JP)
- Kanagawa Cancer Center
- Yokohama City University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-09-30
- DOI
- https://doi.org/10.21873/anticanres.17286
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28